COPD

Over 16 months, a greater rate of patients reported returning visits, proper inhaler use understadning, and overall satisfcation.

AstraZeneca announced that the first of its 2 phase 3 trials of benralizumab for severe COPD failed to meet its primary efficacy endpoint.

The expanded indication was granted based on data from the IMPACT trial, in which it showed superiority to FF/VI and UMEC/VI.

In total, 35% of all HCPs polled responded that the inhalation device is “highly important” when determining medication for a newly diagnosed, stable patient with COPD.

The 10,000-plus participant IMPACT study reported the triple-combination therapy fared better in exacerbation reduction than FF/VI or FF/UMEC.

Many studies have already shown that short-term exposure to fine particle pollution can have a negative effect on lung function, but just 2 exist on the long-term effects, with inconsistent results.

Inhaled anticholinergic bronchodilator tiotropium as an add-on therapy has the potential to reduce exacerbations.

The first once-daily, triple-therapy inhaler drug was originally approved by the FDA in September.

The biologic agent has shown efficacy in reducing asthma exacerbations and improving patient quality of life.

As COPD exacerbations continue to plague patients, the AIRWISE trial will examine LAMA/LABA/ICS combinations.

The FDA approved the inhaler treatment based on 2 Phase III-B studies running 6 months and 12 months, respectively, to compare the drug’s efficacy in COPD exacerbation care.